MedPath

Examination of additive effects of dulaglutide and empagliflozin to type 2 diabetic patients with poor glycemic control despite insulin administration.

Not Applicable
Conditions
type 2 diabetes mellitus
Registration Number
JPRN-UMIN000024703
Lead Sponsor
Social medical corporations Aijinkai Chibune hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with 75 years old and over,category 2,3. Patients who have not taken medicine for 3 months and over. Patients with impaired liver or kidney functions,who need adjustment of medicine.Patients with collagen disease or cancer.Patients who have economic reasons,and judged not to be appropriate by doctors.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HbA1c(%) For patients of 65 years old and over,we follow HbA1c with causion to lower limit.
Secondary Outcome Measures
NameTimeMethod
We assess body weight,accomplishment rates of HbA1c under 7%,blood pressure,renal function,and body fat.
© Copyright 2025. All Rights Reserved by MedPath